OncXerna Therapeutics

OncXerna Therapeutics Utilizes Innovative RNA-Based Biomarker Platform to Advance Precision MedicineOncXerna Therapeutics aims to leverage its expertise in understanding the dominant biology of the tumor microenvironment to prospectively identify disease characteristics in patients, offering next-generation precision medicine to a broader cancer patient population. This enables the company to match these patients with clinical-stage therapies that have known mechanisms of action, directly addressing these biological issues and significantly improving patient outcomes post-treatment. Current precision medicines only target 10% of cancers — oncogenic driver DNA mutations in a few genes. By identifying the dominant biology of an individual’s cancer at the RNA level, the company provides more meaningful treatment options for a larger number of cancer patients, thereby advancing precision medicine beyond single-gene mutations.